Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy

Transplantation Proceedings

Volumn 38, Issue 2, 2006, Pages 358-361

  Yakupoglu, Y K ^a   Buell, J F ^b   Woodle, S ^b   Kahan, B D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; RITUXIMAB; THYMOCYTE ANTIBODY; TSUKUBAENOLIDE;

ADULT; AGED; BLADDER TUMOR; BRAIN TUMOR; BREAST TUMOR; CONFERENCE PAPER; CONTROLLED STUDY; DEMOGRAPHY; DRUG FORMULATION; ENDOMETRIUM CANCER; FEMALE; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INDIVIDUALIZATION; ISRAEL; KIDNEY CARCINOMA; KIDNEY TRANSPLANTATION; LABORATORY TEST; LEUKEMIA; LUNG TUMOR; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRIORITY JOURNAL; SKIN TUMOR; ULTRAVIOLET B RADIATION;

DATABASES, FACTUAL; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; NEOPLASMS; PREDNISONE; REGISTRIES; SIROLIMUS; TREATMENT OUTCOME;

EID: 33645067673     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.01.019     Document Type: Conference Paper

References (21)

1. I. Penn Cancers in cyclosporine-treated vs azathioprine-treated patients Transplant Proc 28 1996 876
2. A.G. Sheil, A.P. Disney, T.H. Mathew De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation Transplant Proc 25 1993 1383
3. N.J. London, S.M. Farmery, E.J. Will Risk of neoplasia in renal transplant patients Lancet 346 1995 403
4. B.L. Kasiske, J.J. Snyder, D.T. Gilbertson Cancer after kidney transplantation in the United States Am J Transplant 4 2004 905
5. G. Opelz, B. Dohler Lymphomas after solid organ transplantation a collaborative transplant study report Am J Transplant 4 2004 222
6. M. Hojo, T. Morimoto, M. Maluccio Cyclosporine induces cancer progression by a cell-autonomous mechanism Nature 397 1999 530
7. S.N. Sehgal Rapamune (RAPA, rapamycin, sirolimus) mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression Clin Biochem 31 1998 335
8. F.L. Luan, M. Hojo, M. Maluccio Rapamycin blocks tumor progression unlinking immunosuppression from antitumor efficacy Transplantation 73 2002 1565
9. M. Guba, P. von Breitenbuch, M. Steinbauer Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis involvement of vascular endothelial growth factor Nat Med 8 2002 128
10. B.D. Kahan, S.M. Stepkowski, K.L. Napoli The development of sirolimus The University of Texas Houston experience P. Terasaki Clinical Transplants 2000 2001 UCLA Tissue Typing Laboratory Los Angeles, Calif 145
11. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.gov). 2002:Sub (1973-2000): released April 2003
12. B.D. Kahan, Y.K. Yakupoglu, L. Schoenberg Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients Transplantation 80 2005 749
13. C.P. Eng, S.N. Sehgal, C. Vezina Activity of rapamycin (AY-22,989) against transplanted tumors J Antibiot (Tokyo) 37 1984 2131
14. G.J. Wiederrecht, C.J. Sabers, G.J. Brunn Mechanism of action of rapamycin new insights into the regulation of G1-phase progression in eukaryotic cells Prog Cell Cycle Res 1 1995 53
15. H. Hosoi, M.B. Dilling, T. Shikata Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells Cancer Res 59 1999 886
16. B.K. Law, A. Chytil, N. Dumont Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells Mol Cell Biol 22 2002 8184
17. H. Hosoi, M.B. Dilling, L.N. Liu Studies on the mechanism of resistance to rapamycin in human cancer cells Mol Pharmacol 54 1998 815
18. G. Stallone, A. Schena, B. Infante Sirolimus for Kaposi's sarcoma in renal transplant recipients N Engl J Med 352 2005 1317
19. S. Kawamata, H. Sakaida, T. Hori The upregulation of p 27kipl by rapamycin results in G1 arrest in exponentially growing T-cell lines Blood 92 1998 561
20. A.K. Perl, P. Wilgenbus, U. Dahl A causal role for E-cadherin in the transition from adenoma to carcinoma Nature 392 1998 190
21. W.S. Cherikh, M. Kauffman, F.L. Delmonico A multivariate analysis of discharge immunosuppression and post-transplant malignancy [Abstract 868] Am J Transplant 1 2001 353